Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Henderson Lori M.. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Henderson Lori M. har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:MRNA / Moderna, Inc. | General Counsel and Secretary | 328 352 |
US:AMRI / Albany Molecular Research, Inc. | SVP, Secretary & Gen Counsel | 0 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Henderson Lori M.. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Henderson Lori M. som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2021-05-28 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 328 352 | −1,97 | |||
2021-05-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 174,20 | −1 149 720 | 156 954 |
2021-05-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 14,85 | 98 010 | 111 390 |
2021-05-27 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 334 952 | −1,93 | |||
2021-05-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 166,58 | −1 099 428 | 150 089 |
2021-05-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 14,85 | 98 010 | 111 390 |
2021-05-21 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 341 552 | −1,90 | |||
2021-05-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 159,92 | −1 055 472 | 144 088 |
2021-05-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 14,85 | 98 010 | 111 390 |
2021-05-20 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 348 152 | −1,86 | |||
2021-05-20 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 160,16 | −1 057 056 | 144 304 |
2021-05-20 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 14,85 | 98 010 | 111 390 |
2021-05-14 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 354 752 | −1,83 | |||
2021-05-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 152,60 | −1 007 160 | 137 493 |
2021-05-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 14,85 | 98 010 | 111 390 |
2021-05-13 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 170 | 361 352 | −1,68 | |||
2021-05-13 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −430 | 93 046 | −0,46 | |||
2021-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 151,31 | −998 646 | 136 330 |
2021-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 170 | 7 501 | 463,56 | 14,85 | 91 624 | 111 390 |
2021-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 430 | 1 331 | 47,72 | 20,93 | 9 000 | 27 858 |
2021-05-07 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 93 476 | −6,59 | |||
2021-05-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 147,82 | −975 612 | 133 186 |
2021-05-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
2021-05-06 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 100 076 | −6,19 | |||
2021-05-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 185,25 | −1 222 650 | 166 910 |
2021-05-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
2021-04-30 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 106 676 | −5,83 | |||
2021-04-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 182,49 | −1 204 434 | 164 423 |
2021-04-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
2021-04-29 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 113 276 | −5,51 | |||
2021-04-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 178,29 | −1 176 714 | 160 639 |
2021-04-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
2021-04-23 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 119 876 | −5,22 | |||
2021-04-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 168,26 | −1 110 516 | 151 602 |
2021-04-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
2021-04-22 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 126 476 | −4,96 | |||
2021-04-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 160,32 | −1 058 112 | 144 448 |
2021-04-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
2021-04-16 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 133 076 | −4,73 | |||
2021-04-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 158,76 | −1 047 816 | 143 043 |
2021-04-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
2021-04-14 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 139 676 | −4,51 | |||
2021-04-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 146,62 | −967 692 | 132 105 |
2021-04-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
2021-04-09 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 146 276 | −4,32 | |||
2021-04-09 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 132,85 | −876 810 | 119 698 |
2021-04-09 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
2021-04-08 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 152 876 | −4,14 | |||
2021-04-08 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 130,01 | −858 066 | 117 139 |
2021-04-08 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
2021-04-02 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 159 476 | −3,97 | |||
2021-04-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 132,51 | −874 566 | 119 392 |
2021-04-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
2021-04-01 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 166 076 | −3,82 | |||
2021-04-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 123,30 | −813 780 | 111 093 |
2021-04-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
2021-03-26 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 172 676 | −3,68 | |||
2021-03-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 126,88 | −837 408 | 114 319 |
2021-03-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
2021-03-25 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 179 276 | −3,55 | |||
2021-03-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 145,55 | −960 630 | 131 141 |
2021-03-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 20,93 | 138 138 | 156 996 |
2021-03-19 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −216 | 185 876 | −0,12 | |||
2021-03-19 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 384 | 118 155 | −5,13 | |||
2021-03-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 144,39 | −952 974 | 130 095 |
2021-03-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 216 | 7 501 | 2,96 | 20,93 | 4 521 | 156 996 |
2021-03-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 384 | 7 285 | 708,55 | 25,93 | 165 537 | 188 900 |
2021-03-18 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 124 539 | −5,03 | |||
2021-03-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 148,50 | −980 100 | 133 798 |
2021-03-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 25,93 | 171 138 | 194 501 |
2021-03-12 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 131 139 | −4,79 | |||
2021-03-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 133,29 | −879 714 | 120 094 |
2021-03-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 25,93 | 171 138 | 194 501 |
2021-03-10 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 137 739 | −4,57 | |||
2021-03-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 127,11 | −838 926 | 114 526 |
2021-03-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 25,93 | 171 138 | 194 501 |
2021-03-05 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 144 339 | −4,37 | |||
2021-03-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 128,58 | −848 628 | 115 851 |
2021-03-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 25,93 | 171 138 | 194 501 |
2021-03-04 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −6 600 | 150 939 | −4,19 | |||
2021-03-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −6 600 | 901 | −87,99 | 153,77 | −1 014 882 | 138 547 |
2021-03-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 6 600 | 7 501 | 732,52 | 25,93 | 171 138 | 194 501 |
2020-10-23 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −32 000 | 367 522 | −8,01 | |||
2020-10-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −700 | 681 | −50,69 | 71,39 | −49 973 | 48 617 |
2020-10-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −15 455 | 1 381 | −91,80 | 70,56 | −1 090 505 | 97 443 |
2020-10-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −14 148 | 16 836 | −45,66 | 69,84 | −988 096 | 1 175 826 |
2020-10-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −1 697 | 30 984 | −5,19 | 68,70 | −116 584 | 2 128 601 |
2020-10-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 32 000 | 32 681 | 4 698,97 | 14,85 | 475 200 | 485 313 |
2020-06-19 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −64 000 | 399 522 | −13,81 | |||
2020-06-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −64 000 | 681 | −98,95 | 63,03 | −4 033 920 | 42 923 |
2020-06-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 64 000 | 64 681 | 9 397,94 | 14,85 | 950 400 | 960 513 |
2020-06-04 |
|
4/A | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −64 000 | 0 | −100,00 | 70,00 | −4 480 000 | |
2020-05-22 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
M - Exercise | X | −64 000 | 463 522 | −12,13 | |||
2020-05-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | −64 000 | 0 | −100,00 | 70,00 | −4 480 000 | |
2020-05-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | X | 64 000 | 64 000 | 14,85 | 950 400 | 950 400 | |
2020-03-03 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
A - Award | 157 539 | 157 539 | |||||
2019-03-11 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
A - Award | 186 092 | 186 092 | |||||
2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | −44 251 | 0 | −100,00 | 3,34 | −147 798 | ||
2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | −29 066 | 0 | −100,00 | 5,98 | −173 815 | ||
2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | −22 893 | 0 | −100,00 | 4,70 | −107 597 | ||
2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | −29 167 | 0 | −100,00 | 11,32 | −330 170 | ||
2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | −4 375 | 0 | −100,00 | 15,76 | −68 950 | ||
2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | −4 375 | 0 | −100,00 | 15,76 | −68 950 | ||
2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | −4 375 | 0 | −100,00 | 15,76 | −68 950 | ||
2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | −17 500 | 0 | −100,00 | 15,76 | −275 800 | ||
2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | −17 500 | 0 | −100,00 | 18,82 | −329 350 | ||
2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | −4 375 | 0 | −100,00 | 18,82 | −82 338 | ||
2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | −4 375 | 0 | −100,00 | 18,82 | −82 338 | ||
2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | −17 500 | 0 | −100,00 | 16,50 | −288 750 | ||
2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
D - Sale to Issuer | −50 000 | 0 | −100,00 | 16,88 | −844 000 | ||
2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
D - Sale to Issuer | −66 717 | 0 | −100,00 | 21,75 | −1 451 095 | ||
2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 4 722 | 66 717 | 7,62 | ||||
2017-09-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
G - Gift | −9 857 | 52 138 | −15,90 | ||||
2017-03-06 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −432 | 61 995 | −0,69 | 14,52 | −6 273 | 900 167 | |
2017-02-10 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
A - Award | 44 251 | 44 251 | |||||
2017-02-10 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 6 747 | 62 427 | 12,12 | ||||
2017-02-10 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 8 990 | 55 680 | 19,25 | ||||
2017-02-07 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −504 | 46 690 | −1,07 | 18,52 | −9 334 | 864 699 | |
2017-02-07 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −674 | 47 194 | −1,41 | 18,52 | −12 482 | 874 033 | |
2017-02-07 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −2 363 | 47 868 | −4,70 | 18,52 | −43 763 | 886 515 | |
2017-02-01 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −553 | 50 231 | −1,09 | 18,11 | −10 015 | 909 683 | |
2017-02-01 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −553 | 50 231 | −1,09 | 18,11 | −10 015 | 909 683 | |
2016-11-17 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | −6 000 | 51 337 | −10,46 | 17,00 | −102 000 | 872 729 | |
2016-11-03 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −409 | 57 337 | −0,71 | 15,09 | −6 172 | 865 215 | |
2016-03-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −421 | 57 746 | −0,72 | 15,33 | −6 454 | 885 246 | |
2016-02-19 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
D - Sale to Issuer | −1 459 | 58 167 | −2,45 | ||||
2016-02-19 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −463 | 59 626 | −0,77 | 15,37 | −7 116 | 916 452 | |
2016-02-08 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
A - Award | 29 066 | 29 066 | 15,77 | 458 371 | 458 371 | ||
2016-02-08 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 12 682 | 60 089 | 26,75 | 15,77 | 199 995 | 947 604 | |
2016-02-05 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −684 | 47 407 | −1,42 | 16,16 | −11 053 | 766 097 | |
2016-02-01 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −554 | 48 091 | −1,14 | 15,97 | −8 847 | 768 013 | |
2016-02-01 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −554 | 48 091 | −1,14 | 15,97 | −8 847 | 768 013 | |
2015-11-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 5 000 | 49 199 | 11,31 | 19,16 | 95 800 | 942 653 | |
2015-06-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
D - Sale to Issuer | −1 459 | 44 199 | −3,20 | ||||
2015-06-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −476 | 45 658 | −1,03 | ||||
2015-03-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
A - Award | 22 893 | 22 893 | 17,05 | 390 326 | 390 326 | ||
2015-03-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 10 588 | 46 134 | 29,79 | 17,05 | 180 525 | 786 585 | |
2015-02-19 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
D - Sale to Issuer | −1 458 | 35 546 | −3,94 | ||||
2015-02-19 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −464 | 37 004 | −1,24 | ||||
2015-02-06 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −1 582 | 37 468 | −4,05 | ||||
2015-02-03 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
D - Sale to Issuer | −1 459 | 39 050 | −3,60 | ||||
2015-02-03 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −554 | 40 509 | −1,35 | ||||
2014-10-01 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | X | −1 000 | 41 063 | −2,38 | 21,48 | −21 480 | 882 033 |
2014-09-03 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | X | −2 500 | 42 063 | −5,61 | 19,56 | −48 900 | 822 752 |
2014-08-13 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to Purchase Common Stock |
M - Exercise | 30 000 | 50 000 | 150,00 | 4,87 | 146 100 | 243 500 | |
2014-08-13 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | −30 000 | 44 563 | −40,23 | 19,05 | −571 500 | 848 925 | |
2014-08-13 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
M - Exercise | 30 000 | 74 563 | 67,32 | 4,87 | 146 100 | 363 122 | |
2014-08-01 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | X | −2 500 | 44 563 | −5,31 | 18,56 | −46 400 | 827 089 |
2014-07-02 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | X | −2 500 | 47 063 | −5,04 | 20,62 | −51 550 | 970 439 |
2014-06-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −476 | 49 563 | −0,95 | ||||
2014-06-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
D - Sale to Issuer | −1 458 | 50 039 | −2,83 | ||||
2014-06-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | X | −2 500 | 51 497 | −4,63 | 16,32 | −40 800 | 840 431 |
2014-05-01 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | X | −2 500 | 53 997 | −4,43 | 15,73 | −39 325 | 849 373 |
2014-04-02 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
S - Sale | X | −2 500 | 56 497 | −4,24 | 18,74 | −46 850 | 1 058 754 |
2014-02-19 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −1 038 | 58 997 | −1,73 | ||||
2014-02-06 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to purchase Common Stock |
A - Award | 29 167 | 29 167 | 10,43 | 304 212 | 304 212 | ||
2014-02-06 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 14 584 | 60 035 | 32,09 | 10,43 | 152 111 | 626 165 | |
2014-02-06 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −948 | 45 451 | −2,04 | ||||
2014-02-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −1 106 | 46 399 | −2,33 | ||||
2013-06-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
F - Taxes | −477 | 47 505 | −0,99 | ||||
2013-06-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
D - Sale to Issuer | −1 458 | 47 982 | −2,95 | ||||
2013-02-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to purchase Common Stock |
A - Award | 35 000 | 35 000 | 5,99 | 209 650 | 209 650 | ||
2013-02-04 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 11 666 | 49 440 | 30,88 | 5,99 | 69 879 | 296 146 | |
2012-06-12 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
D - Sale to Issuer | −1 458 | 37 774 | −3,72 | ||||
2012-02-21 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Option to purchase Common Stock |
A - Award | 35 000 | 35 000 | 2,93 | 102 550 | 102 550 | ||
2012-02-21 |
|
4 | AMRI |
ALBANY MOLECULAR RESEARCH INC
Common Stock |
A - Award | 11 666 | 39 232 | 42,32 | 2,93 | 34 181 | 114 950 |